Antifibrinolytic Agent; Antihemophilic Agent; Hemostatic Agent:
Indicated for short-term use to reduce or prevent hemorrhage and reduce the need for replacement therapy during and after tooth extraction in patients with hemophilia and for the treatment of cyclic heavy menstrual bleeding in women of reproductive potential.

Forms a reversible complex that displaces plasminogen from fibrin resulting in inhibition of fibrinolysis; it also inhibits the proteolytic activity of plasmin.

Absorption
1. Bioavailability: ~45%
2. Time to peak:Single dose: Mean: 2.5 hours
Excretion:Urine (>95% as unchanged drug).
Pharmakodynamics
1. Duration:Antifibrinolytic concentrations remain in tissues for about 17 hours and in the serum for 7 to 8 hours.
2. Half-life Elimination:The biological half-life of tranexamic acid in synovial fluid is approximately 3 hours.
3. Clearance:The elimination half-life of tranexamic acid is approximately 2 hours.

1.Hypersensitivity to tranexamic acid or any component of the formulation.
2.History of thrombosis or thromboembolism, including retinal vein or retinal artery occlusion; intrinsic risk of thrombosis or thromboembolism

B

1. Tranexamic acid is present in the mother's milk at a concentration about one-hundredth of the corresponding serum concentration.
2.Tranexamic acid should be used during lactation only if clearly needed.

Common(>10%):Abdominal pain (20%)、Headache (50%)、Back pain (21%), musculoskeletal pain (11%)
警語(Caution):Retinal venous and arterial occlusions have been reported in patients receiving tranexamic acid.

適應症:
1.Abnormal uterine bleeding:1 to 1.5 g 3 times daily for up to 5 days
2.Tooth extraction in patients with hemostatic defects: 25 mg/kg (usual dose range: 1 to 1.5 g) 3 to 4 times daily

Patients with impaired renal function may require dose adjustment.

No dosage adjustment is necessary.